Eosinophil-related diseases during treatment with glucagon-like peptide one receptor (GLP-1 RA): a case report and review of the literature.

Autor: Posso-Osorio I; Universidad Icesi, Facultad de Ciencias de la Salud, Cali, 760031, Colombia.; Unit of Rheumatology, Fundación Valle del Lili, Unidad de Reumatología, Cali, 760031, Colombia.; Universidad Icesi, CIRAT: Centro de Investigación en Reumatología, Autoinmunidad y Medicina Traslacional, Cali, 760031, Colombia., Vargas-Potes CJ; Universidad Icesi, Facultad de Ciencias de la Salud, Cali, 760031, Colombia., Mejía M; Fundación Valle del Lili, Unidad de Radiología, Cali, 760031, Colombia., Cañas CA; Universidad Icesi, Facultad de Ciencias de la Salud, Cali, 760031, Colombia. cacanas@icesi.edu.co.; Unit of Rheumatology, Fundación Valle del Lili, Unidad de Reumatología, Cali, 760031, Colombia. cacanas@icesi.edu.co.; Universidad Icesi, CIRAT: Centro de Investigación en Reumatología, Autoinmunidad y Medicina Traslacional, Cali, 760031, Colombia. cacanas@icesi.edu.co.
Jazyk: angličtina
Zdroj: Clinical rheumatology [Clin Rheumatol] 2023 Sep; Vol. 42 (9), pp. 2501-2506. Date of Electronic Publication: 2023 May 18.
DOI: 10.1007/s10067-023-06612-w
Abstrakt: Glucagon-like peptide one-receptor agonists (GLP-1 RA) are drugs that differ in their pharmacological composition and homology to human GLP-1 and are used most frequently for the treatment of type 2 diabetes and weight loss. There are isolated reports of eosinophilic adverse reactions associated with GLP-1 RA. We present the case of a 42-year-old female patient who, after starting weekly subcutaneous semaglutide, developed eosinophilic fasciitis with favorable clinical evolution after the discontinuation of semaglutide and the initiation of immunosuppression. A review of the eosinophilic adverse events that have been previously reported with GLP-1 RA is provided.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz: